SCHEMBL10187005

SCHEMBL10187005

[C-]#[N+]c1cccc(NC(=O)c2ccc(S(=O)(=O)N3CCCc4ccccc43)cc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 3/20 0.60
KMT2A Q03164 8/20 0.59
MEN1 O00255 7/20 0.59
MAPT P10636 6/20 0.58
ALDH1A1 P00352 2/20 0.58
CASP3 P42574 1/20 0.58
SENP8 Q96LD8 1/20 0.58
SENP7 Q9BQF6 1/20 0.58
SENP6 Q9GZR1 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
TP53 P04637 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
NR3C1 P04150 2/20 0.56
LMNA P02545 4/20 0.56
KDM4E B2RXH2 2/20 0.56
HPGD P15428 2/20 0.56
MAPK1 P28482 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL663265 0.86 KMT2A (0.74) RORCKMT2AMEN1MAPTALDH1A1
SCHEMBL664662 0.86 RORC (0.64) RORCKMT2AMEN1MAPTALDH1A1
SCHEMBL10186956 0.85 NR3C1 (0.66) RORCKMT2AMEN1MAPTALDH1A1
SCHEMBL663814 0.85 MAPT (0.76) RORCKMT2AMEN1MAPTALDH1A1
SCHEMBL665609 0.85 MEN1 (0.65) RORCKMT2AMEN1MAPTALDH1A1
SCHEMBL662912 0.83 NR3C1 (0.71) RORCKMT2AMEN1MAPTALDH1A1
SCHEMBL29978306 0.83 MAPT (0.68) RORCKMT2AMEN1MAPTALDH1A1
SCHEMBL664117 0.83 MAPT (0.68) RORCKMT2AMEN1MAPTALDH1A1
SCHEMBL663769 0.82 KMT2A (0.59) RORCKMT2AMEN1MAPTALDH1A1
SCHEMBL29978377 0.82 KMT2A (0.59) RORCKMT2AMEN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170066755-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC. 2017-03-09 US disclosed
US-9416101-B2 Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2016-08-16 US disclosed
US-20150051177-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC. 2015-02-19 US disclosed
US-8901306-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2014-12-02 US disclosed
US-20120046250-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066755-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL WNT3A, WNT1, WNT3 RORC 522/4885KMT2A 3839/4885MEN1 4226/4885
US-20150051177-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL WNT3A, WNT1, WNT3 RORC 522/4885KMT2A 3839/4885MEN1 4226/4885
US-20120046250-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL WNT3A, WNT1, WNT3 RORC 522/4885KMT2A 3839/4885MEN1 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.